Investigating the role of stereochemistry in the activity of anticancer acylfulvenes: synthesis, reductase-mediated bioactivation, and cellular toxicity.

Acylfulvenes comprise a family of semisynthetic natural product derivatives with potent antitumor activities. Previous studies indicated that acylfulvenes are bioactivated by NADPH-dependent alkenal/one reductase (AOR), presumably generating intermediates with the capacity to alkylate cellular targets, such as DNA, proteins, and glutathione. This process is thought to induce apoptosis, and the chemical and biochemical pathways involved are topics of current investigation. In this study, four acylfulvene analogues were synthesized: (-)-acylfulvene, (+)-acylfulvene, (-)-(hydroxymethyl)acylfulvene, and (+)-(hydroxymethyl)acylfulvene. These compounds were synthesized by a chiral-resolution method, described for the first time in this report, and by asymmetric synthesis using a method formally demonstrated previously. Cell toxicity studies indicate a positive correlation between AOR level and acylfulvene sensitivity. The absolute configuration of acylfulvene analogues has a significant influence on cytotoxicity. (-)-(Hydroxymethyl)acylfulvene is 25 times more potent than (+)-(hydroxymethyl)acylfulvene in cells transfected with an AOR overexpression vector. Based on kinetic parameters, the rates of AOR-mediated activation are more strongly dependent on acylfulvene substitution than on absolute stereochemistry. These data support the role of AOR-mediated metabolism and indicate the involvement of other stereochemically dictated pathways, such as transport and biomolecule binding, in contributing to the cytotoxicity of acylfulvenes.

[1]  Huiyun Liang,et al.  Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells. , 2004, Molecular cancer therapeutics.

[2]  E. Raymond,et al.  Irofulven Cytotoxicity Depends on Transcription-Coupled Nucleotide Excision Repair and Is Correlated with XPG Expression in Solid Tumor Cells , 2004, Clinical Cancer Research.

[3]  Xiang Yu,et al.  NADPH Alkenal/One Oxidoreductase Activity Determines Sensitivity of Cancer Cells to the Chemotherapeutic Alkylating Agent Irofulven , 2004, Clinical Cancer Research.

[4]  M. Kelner,et al.  Synthesis and biological activity of enantiomers of antitumor irofulven. , 2004, The Journal of organic chemistry.

[5]  D. Boger,et al.  Mechanisms of in situ activation for DNA-targeting antitumor agents. , 2002, Chemical reviews.

[6]  J. Woynarowski,et al.  Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). , 2000, Biochemical pharmacology.

[7]  Kay M. Brummond,et al.  A Rapid Synthesis of Hydroxymethylacylfulvene (HMAF) Using the Allenic Pauson−Khand Reaction. A Synthetic Approach to Either Enantiomer of This Illudane Structure , 2000 .

[8]  J. Woynarowski,et al.  Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). , 1999, Biochemical pharmacology.

[9]  Jianliang Lu,et al.  A Short Synthesis of the Potent Antitumor Agent (±)-Hydroxymethylacylfulvene Using an Allenic Pauson-Khand Type Cycloaddition , 1999 .

[10]  T. Mcmorris,et al.  Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug. , 1999, Bioorganic & medicinal chemistry.

[11]  S. Aaronson,et al.  Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. , 1995, Cancer research.

[12]  M. Montoya,et al.  Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. , 1995, Cancer research.

[13]  T. Mcmorris,et al.  Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity. , 1990, Journal of the National Cancer Institute.

[14]  H. Eichholtz-Wirth,et al.  The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. , 1986, British Journal of Cancer.

[15]  D. Dess,et al.  Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones , 1983 .

[16]  M. Kelner,et al.  Metabolism of antitumor acylfulvene by rat liver cytosol. , 1999, Biochemical pharmacology.

[17]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.